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ABSTRACT  
 
Objective: Statin use over the age of 80 years is weakly evidence-based. This study aimed 
to estimate rates of statin inception and deprescribing by frailty level in people aged 80 years 
or older.  
Methods: A cohort of 212,566 participants aged ≥80 years was sampled from the UK 
Clinical Practice Research Datalink. Statin inception was defined as a first-ever prescription 
in a non-statin user; deprescribing was defined as a last ever statin prescription more than 6 
months before the end of participant records. Rates were estimated in a time-to-event 
framework allowing for mortality as a competing risk. Covariates were age, gender, frailty 
category and prevention type. 
Results: Prevalent statin use increased from 2001-5 (9.9%) to 2011-15 (49.3%). Inception 
of statins in never-users was low overall at 2.4% per year (95% confidence interval (CI) 2.2% 
to 2.6%) and declined with age. Deprescribing of statins in current users occurred at a rate 
of 5.6% (95% CI 5.4% to 5.9%) per year overall and increased with age, reaching 17.8% per 
year (95% CI 6.7% to 28.9%) among centenarians. Deprescribing was slightly higher for 
primary prevention (6.5% per year) than secondary prevention (5.2% per year) indications 
(P<0.001). Deprescribing increased with frailty level being 5.0% per year in ‘fit’ participants 
and 7.1% in ‘severe’ frailty (P<0.001). 
Conclusions: Statin use has increased in the over-80s but deprescribing is common and 
increases with age and frailty level. These paradoxical findings highlight a need for better 
evidence to inform statin use and discontinuation for people aged ≥80 years.  
 
Key words: cardiovascular disease; statin therapy; primary care; 80 and over; frailty 
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BACKGROUND 
 
CVD prevention is of increasing importance in people aged 80 years and over. [1,2] The use 
of statins has become more widespread [3] and this trend extends to people over 80 
years.[4, 5] However, prescribing of statins in this age-group, especially for primary 
prevention of CVD, remains controversial and poorly evidence-based.[6, 7] Current 
guidelines encourage individualised decisions for older people.[8-10] This may require 
consideration of level of frailty because frailty is often associated with clinical indications for 
prescribing but the risks of harms may increase with frailty level.[10] This study aimed to 
evaluate statin prescribing in people aged 80 years and older.  
 
METHODS 
Study Design and Participants 
A population-based cohort study was conducted in the UK Clinical Practice Research 
Datalink (CPRD). [11, 12] Eligible participants were selected from patients aged at least 80 
years old and registered with the CPRD between 1st January 2001 and the 31st December 
2015. For each calendar year from 2001 to 2015, and for each single year of age from 80 to 
105 years, 1,000 patients were sampled from the population of patients registered during 
that year. The final cohort was 212,566 participants because there were fewer eligible at the 
maximum at older ages and, because sampling was performed with replacement, some 
participants were sampled in multiple years. The sample size was sufficient to estimate a 
proportion with precision (confidence interval width) of less than +/- 1%. Person-time was 
analysed for each participant from the later of start of their record in CPRD or the 1st January 
in the year in which they were sampled, to the earlier of the date of death or end of CPRD 
record. 
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Study Measures 
Statin drugs were considered as a single group based on all statins available for prescription 
between 2001 and 2015. Covariates were gender, five-year age group, co-morbidity and 
frailty category. Co-morbidity was determined from analysis of Read medical codes, and  
drug product codes, for diabetes mellitus,[13] coronary heart disease[14] and stroke[15] as 
reported previously. Participants with one or more of these conditions were classified as 
having a secondary prevention indication from the date of the earliest diagnosis. Diabetes 
mellitus confers a similar level of CVD-risk as a previous cardiovascular event.[16] Frailty 
status was assessed using a previously published 36-item electronic Frailty Index (eFI)[17] 
based on a cumulative deficit model.[18] Categories of fit, mild, moderate and severe frailty 
were defined.[17] The 36 items included in the eFI encompass common cardiovascular 
diseases and diabetes.  
 
Analysis 
Participants were classified as prevalent statin users if they received one or more statin 
prescriptions within 12 months of their entry to the study. Statin inception was defined as a 
first-ever statin prescription recorded more than 12 months after entry to the study. Statin 
deprescribing [19]  among prevalent statin users was defined as a last ever statin 
prescription occurring more than six months before the end of the participant’s record. 
Previous research has shown that the average duration of prescriptions for long-term 
conditions in CPRD is about 90 days.[20] We estimated rates of inception and deprescribing 
as the cumulative incidence of each outcome allowing for competing risks.[21] Analyses 
were performed using the ‘cmprsk’, ‘ggplot2’  and ‘forestplot’ packages in the R program.[22]  
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RESULTS 
The cohort comprised 212,566 participants including 69,001 men and 143,565 women aged 
80 years or older. In 2001-2005, 12% of men and 9% of women were prescribed statins 
(Table 1), increasing to 55% of men and 46% of women in 2011-2015. Statin prescribing 
generally decreased in frequency with increasing age group but by 2011-2015, 12% of 
centenarians were prescribed statins. Statin prescribing was considerably higher in 
participants with secondary prevention indications, in whom 80% were prescribed statins in 
2011-2015 compared to 30% with primary prevention participants were prescribed statins 
(P<0.001). Statin prescribing also increased with frailty level from 26% of ‘fit’ patients to 69% 
of ‘severely frail’ patients in 2011-2015 (P<0.001). Data are presented for all person-time by 
year in Supplementary Figure 1 and Supplementary Table 1. 
 
Figure 1 presents a forest plot showing rates of inception and deprescribing of statins during 
the period 2011-2015 according to levels of covariates of the whole sample. Among never-
users of statins the rate of statin inception was 2.4% per year (95% confidence interval 2.2% 
to 2.60%). The rate of statin inception declined with age (P<0.001) being 3.3% per year 
(2.9% to 3.7%) at 80 to 84 years, but 1.6% (1.3% to 2.0%) at 90-94 years and 0.5% (-0.5% 
to 1.4%) among centenarians. Statin inception was only slightly higher in men than women 
(P<0.001) and was non-significantly higher for secondary prevention (3.0% per year) than 
primary prevention indications (2.3%) (P=0.177). Statin inception was but lowest among ‘fit’ 
participants but rates were generally similar among those with ‘mild’, ‘moderate’ or ‘severe’ 
frailty, though overall differences by frailty category were not significant (P=0.123). 
 
The rate of statin deprescribing among statin users was 5.6% per year overall (95% 
confidence interval 5.4% to 5.9%). The rate of statin deprescribing increased substantially 
with age (P<0.001) being 4.2% per year (3.9% to 4.5%) at 80 to 84 years, 8.1% (7.3% to 
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8.8%) at 90 to 94 years and 17.8% (6.7% to 28.9%) among centenarians. Statin 
deprescribing was higher (P<0.001) among women (6.4%, 6.0% to 6.7%) than men (4.5%, 
4.2% to 4.9%) and increased with frailty level (P<0.001), being 5.0% (4.4% to 5.7%) per year 
among ‘fit’ participants but 7.1% (6.4% to 7.8%) among participants with ‘severe’ frailty. 
Deprescribing was also slightly higher (P<0.001) among participants with primary prevention 
(6.5%) than secondary prevention (5.2%) indications.  
 
DISCUSSION 
Main findings 
These data reveal a substantial increase in the use of statins between 2001 and 2015. Statin 
prescribing has increased in the general population following publication of several studies 
that demonstrated reduced mortality and new CVD events from statin therapy in people at 
high risk.[23, 24] Much of the increase in statin use in the over-80s may be accounted for by 
a ‘cohort effect’, with individuals who started statins in their 60s and 70s now reaching older 
ages still taking statins. We find that inception of statins in people aged more than 80 is not a 
frequent event, we also provide estimates of statin deprescribing for relevant population sub-
groups.  
 
Individuals classified as ‘frail’ according to a deficit accumulation model that includes CVD 
conditions [17, 25] are also frequently prescribed statins. Nearly one in four ‘fit’ individuals 
who do not have cardiovascular disease or diabetes are now statin users. Our results show 
that statin inception among never-users of statins in their 80s and 90s only occurs at low 
rates [3] and generally become less frequent with age. The results show that statin 
deprescribing among prevalent statin users occurs at twice the rate of statin inception at 80 
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to 84 years. Among 90 to 94 year olds, statin deprescribing is observed at more than four 
times the rate of statin inception.  
 
Strengths and limitations  
We classified patients’ frailty level according to an established measure of frailty but this 
relied on medical diagnoses coded into electronic health records.[17, 26] This approach may 
not always be consistent with assessment of frailty using physical measures.[25] We 
observed evidence for discontinuation of statin prescriptions but lack of information on the 
reasons for discontinuation is a limitation of this study. We were not able to assess the 
appropriateness of statin prescribing or deprescribing, our results might be compatible either 
with over- or under-use of statins in this age group. One of the main conclusions of the study 
is that clearer recommendations for appropriate use of statins in the over-80s are needed. 
 
Comparison with other studies 
Trends reported in this paper are consistent with those reported from Europe[4] and the U.S. 
[5] Clinical recommendations for the use of statins have been informed by meta-analyses of 
randomised controlled trials but these provide limited evidence for people aged over-80. The 
2013 Cochrane review on statins for the primary prevention of cardiovascular disease 
included 18 trials,[27] nine of these excluded participants aged over 80 and in the remaining 
trials, the mean age of participants was no higher than 66 years. A systematic review of 
clinical trials of statin treatment suggested that statins may reduce mortality in people aged 
over 65 with coronary heart disease.[28] In participants without established CVD, there was 
evidence of reduced incidence of myocardial infarction and stroke but no evidence for 
reduction in mortality.[29] In a review of clinical trial evidence for people aged over 80 years, 
Petersen et al. [30] concluded that there was no evidence from clinical trials that cholesterol-
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lowering treatment was associated with lower mortality. UK recommendations suggest that 
statin use should be based on clinical judgement informed by assessment of patient 
preference, comorbidities, polypharmacy, general frailty and life expectancy.’ [9]  
 
Conclusions 
Widespread statin use is consistent with the elevated risk of CVD in the over-80s but an age-
related increase in deprescribing implies recognition of the limitations of preventive medical 
intervention, and a changing balance of benefits and harms in this age-group. Further 
research may be required to inform deprescribing decisions and promote deprescribing 
strategies where appropriate. 
 
Key Points: 
 The frequency of statin use in people aged 80 to 105 years was evaluated 
 Statin prescription increased rapidly from 2001 to 2015 in men and women 
 Inception of statins was infrequent and decreased with age 
 Deprescribing was more frequent and increased with age and frailty level 
 Statin prescribing and deprescribing have both increased in the over 80’s. More 
evidence is needed concerning appropriate use of statins in this age group 
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Table 1: Prevalent statin use at study entry. Figures are frequencies (column percent). 
   Year of entry to study 
P value  
(test for trend) 
  2001-2005  2006-2010  2011-2015   
  Freq. % Freq. % Freq. %  
         
Total  8,091 / 81,353 9.9 23,293 / 66,817 34.9 31,747 / 64,396 49.3 <0.001 
         
Gender Male 3,013 / 24,251 12.4 8,780 / 22,004 39.9 12,492 / 22,746 54.9 <0.001 
 Female 5,078 / 57,102 8.9 14,513 / 44,813 32.4 19,255 / 41,650 46.2 <0.001 
         
Age Group 80-84 4,367 / 23,673 18.5 10,764 / 23,132 46.5 13,486 / 23,060 58.5 <0.001 
 85-89 2,455 / 22,130 11.1 7,541 / 19,793 38.1 10,103 / 18,981 53.2 <0.001 
 90-94 1,060 / 20,412 5.2 3,863 / 15,327 25.2 6,233 / 14,724 42.3 <0.001 
 95-99 196 / 12,823 1.5 1,096 / 7,989 13.7 1,838 / 6,905 26.6 <0.001 
 100+ 13 / 2,315 0.6 29 / 576 5.0 87 / 726 12.0 <0.001 
         
Frailty Fit 1,956 / 36,500 5.4 3,159 / 17,190 18.4 3,224 / 12,394 26.0 <0.001 
 Mild 3,458 / 28,373 12.2 8,855 / 25,744 34.4 10,587 / 23,052 45.9 <0.001 
 Moderate 1,993 / 12,691 15.7 7,478 / 16,811 44.4 10,954 / 18,814 58.2 <0.001 
 Severe 684 / 3,789 18.0 3,801 / 7,072 53.7 6,982 / 10,136 68.9 <0.001 
         
Prevention 
Type 
Primary 2,251 / 57,155 3.9 7,815 / 43,397 18.0 12,146 / 39,892 30.4 <0.001 
Secondary 5,840 / 24,198 24.1 15,478 / 23,420 66.1 19,601 / 24,504 80.0 <0.001 
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Figure 1: Forest plot showing annual proportion (%) for inception of statins among 
never-users of statins, and deprescribing of statins among statin users. Upper (UL) 
and lower limits (LL) of 95% confidence intervals are shown. 
 
  
 
